Affordable Access

Publisher Website

Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?

Authors
Type
Published Article
Journal
BJU International
1464-4096
Publisher
Wiley Blackwell (Blackwell Publishing)
Publication Date
Volume
116
Issue
2
Pages
220–229
Identifiers
DOI: 10.1111/bju.12880
PMID: 25060664
Source
Medline
Keywords
  • Active Surveillance
  • Cumulative Cancer Length
  • Insignificant Cancer
  • Needle Biopsy
  • Prostate Cancer

Abstract

In patients eligible for AS, a CCL/core of <0.20 mm was significantly associated with insignificant cancer and LV-OCD. However, when parameters of cancer burden were considered, CCL/core did not independently add any additional value for predicting insignificant cancer in patients with biopsy Gleason score 6. The CCL/core was an independent predictor of LV-OCD in the whole population and in group 1 patients, although the model including prostate cancer length showed slightly higher area under the receiver operating characteristic curve.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F